☆ 4.7 Article

Finerenone in type 2 diabetes and renal outcomes: A random-effects model meta-analysis

FRONTIERS IN ENDOCRINOLOGY (2023)

Related references

Note: Only part of the references are listed.

Review Pharmacology & Pharmacy

Efficacy and Safety of Finerenone in Chronic Kidney Disease: A Systematic Review and Meta-Analysis of Randomized Clinical Trials

Ming-Zhu Zhang et al.

Summary: The meta-analysis validates the clinical efficacy and safety of finerenone in patients with CKD. Finerenone demonstrated significant improvements in urinary albumin-to-creatinine ratio (UACR) and estimated glomerular filtration rate (eGFR), leading to renal and cardiovascular benefits. However, the risk of hyperkalemia was higher in the finerenone group compared to the placebo group, while adverse events were similar.

FRONTIERS IN PHARMACOLOGY (2022)

Add to Collection

Review Urology & Nephrology

Clinical perspective-evolving evidence of mineralocorticoid receptor antagonists in patients with chronic kidney disease and type 2 diabetes

Peter Rossing

Summary: Chronic kidney disease (CKD) in type 2 diabetes is a serious problem that current treatments struggle to address. However, novel nonsteroidal mineralocorticoid receptor antagonists (MRAs) show promise in reducing proteinuria and markers of heart failure (HF), with a lower risk of hyperkalemia and renal impairment. Clinical trials have demonstrated the efficacy of the nonsteroidal MRA finerenone in delaying the progression of kidney and cardiovascular disease in CKD patients with type 2 diabetes. The use of nonsteroidal MRAs could be a beneficial addition to the treatment of CKD patients with type 2 diabetes.

KIDNEY INTERNATIONAL SUPPLEMENTS (2022)

Add to Collection

Review Urology & Nephrology

The role of mineralocorticoid receptor activation in kidney inflammation and fibrosis

James M. Luther et al.

Summary: Chronic kidney disease is characterized by progressive scarring in the kidney, leading to the loss of normal tissue and eventual end-stage kidney disease. Aldosterone plays a role in promoting inflammation and fibrosis in the kidney through various mechanisms.

KIDNEY INTERNATIONAL SUPPLEMENTS (2022)

Add to Collection

Article Medicine, General & Internal

Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes

Bertram Pitt et al.

Summary: Finerenone therapy improved cardiovascular outcomes in patients with type 2 diabetes and stage 2 to 4 CKD with moderately elevated albuminuria or stage 1 or 2 CKD with severely elevated albuminuria, compared to placebo. The risk of the primary outcome event was significantly lower in the finerenone group, primarily driven by a reduction in hospitalization for heart failure.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Review Health Care Sciences & Services

Efficacy and safety of finerenone in patients with chronic kidney disease: a systematic review with meta-analysis and trial sequential analysis

Zhangning Fu et al.

Summary: This meta-analysis shows that finerenone has a significant antiproteinuric effect in patients with chronic kidney disease, and also reduces the risk of cardiovascular disorders in these patients. Although the frequency of adverse events was similar between the two groups, the finerenone group had specific risks, such as a lower risk of cardiovascular disorders and a higher risk of hyperkalemia.

ANNALS OF PALLIATIVE MEDICINE (2021)

Add to Collection

Article Cardiac & Cardiovascular Systems

Cardiorenal Protection With the Newer Antidiabetic Agents in Patients With Diabetes and Chronic Kidney Disease: A Scientific Statement From the American Heart Association

Janani Rangaswami et al.

CIRCULATION (2020)

Add to Collection

Article Medicine, General & Internal

Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes

George L. Bakris et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

Add to Collection

Article Urology & Nephrology

Diabetic Kidney Disease Challenges, Progress, and Possibilities

Radica Z. Alicic et al.

CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2017)

Add to Collection

Article Endocrinology & Metabolism

A randomized controlled study of finerenone versus placebo in Japanese patients with type 2 diabetes mellitus and diabetic nephropathy

Shigehiro Katayama et al.

JOURNAL OF DIABETES AND ITS COMPLICATIONS (2016)

Add to Collection

Review Urology & Nephrology

Nonsteroidal antagonists of the mineralocorticoid receptor

Peter Kolkhof et al.

CURRENT OPINION IN NEPHROLOGY AND HYPERTENSION (2015)

Add to Collection

Article Medicine, General & Internal

Effect of Finerenone on Albuminuria in Patients With Diabetic Nephropathy A Randomized Clinical Trial

George L. Bakris et al.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2015)

Add to Collection

Review Peripheral Vascular Disease

Mineralocorticoid Receptor Activation and Mineralocorticoid Receptor Antagonist Treatment in Cardiac and Renal Diseases

Johann Bauersachs et al.

HYPERTENSION (2015)

Add to Collection

Article Cardiac & Cardiovascular Systems

Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial

Bertram Pitt et al.

EUROPEAN HEART JOURNAL (2013)

Add to Collection

Article Medicine, General & Internal

Combined Angiotensin Inhibition for the Treatment of Diabetic Nephropathy

Linda F. Fried et al.

NEW ENGLAND JOURNAL OF MEDICINE (2013)

Add to Collection

Article Medicine, General & Internal

Cardiorenal End Points in a Trial of Aliskiren for Type 2 Diabetes

Hans-Henrik Parving et al.

NEW ENGLAND JOURNAL OF MEDICINE (2012)

Add to Collection

Article Medicine, General & Internal

Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy

BM Brenner et al.

NEW ENGLAND JOURNAL OF MEDICINE (2001)

Add to Collection

© Peeref 2019-2024. All rights reserved.